Fostamatinib

• CAT Number: I005396
• CAS Number: 901119-35-5
• Molecular Formula: C23H26FN6O9P
• Molecular Weight: 580.46
• Purity: 98%
• Synonyms: [6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate
• Target: SYK
• Target Protein: P43405
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: Syk/FLT3:Ki:30 nM IC50:41 nM
• InChI: InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)
• InChIKey: GKDRMWXFWHEQQT-UHFFFAOYSA-N
• SMILES: CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C

Fostamatinib（Cat No.:I005396）is a spleen tyrosine kinase (SYK) inhibitor used for the treatment of chronic immune thrombocytopenia (ITP) in patients who have had an insufficient response to other therapies. By inhibiting SYK, Fostamatinib disrupts the immune system’s destruction of platelets, increasing platelet counts in affected individuals. Its mechanism targets the underlying autoimmune response in ITP, offering an effective treatment option for patients with difficult-to-treat conditions. Fostamatinib is taken orally and has shown clinical efficacy in improving platelet levels, reducing bleeding risks, and enhancing overall patient outcomes.

Reference

[1]. Stephen P McAdoo, et al. Fostamatinib Disodium. Drugs Future. 2011;36(4):273.
[Content Brief]

[2]. Sylvia Braselmann, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008.
[Content Brief]

[3]. Hoon-Suk Cha , et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther. 2006 May;317(2):571-8.
[Content Brief]